CagriSema Weight Loss Results at a Glance Adults without diabetes: 20.4% average, 22.7% with adherence Adults with type 2 diabetes: 13.7% average, 15.7% with adherence Placebo: 3% (non-diabetic) and 3.4% (diabetic) 40.4% of REDEFINE 1 participants reached 25%+ weight loss CagriSema Dosing and Dosage Chart CagriSema Side Effects Nausea Vomiting Diarrhea Constipation Loss of appetite CagriSema vs Tirzepatide, Zepbound, Semaglutide and Retatrutide CagriSema vs Tirzepatide (and Zepbound) Tirzepatide is a single molecule that hits both GLP-1 and GIP receptors, and it is sold as Zepbound for weight loss and Mounjaro for diabetes
Mechanism Overview: How Each Compound Acts GHK-Cu is a naturally occurring tripeptide-copper complex formed endogenously from the cleavage of the 2-macroglobulin C-terminus
Fatigue, lightheadedness, and low mood can reflect the calorie deficit rather than the drug itself
FDA-approved peptides like semaglutide and tirzepatide may be covered when prescribed for approved indications (diabetes, obesity), but compounded peptides, off-label uses, and anti-aging applications are typically out-of-pocket expenses